WASHINGTON (Legal Newsline) – The Federal Trade Commission recently approved a modified final order that resolves charges against Hikma Pharmaceuticals PLC in its acquisition of various drug products and related assets from Ben Venue Laboratories Inc., which the FTC believes is anti-competitive.
To complete the acquisition now, Hikma will need to divest assets related to five generic injectable drugs to Amphastar Pharmaceuticals Inc., a specialty pharmaceutical company based in California.
Hikma and Amphastar changed the price of the divested assets after the FTC accepted the original consent agreement. The agency therefore modified the order to incorporate the revised divestiture agreement.
The FTC voted 3-0-1 to approve the modified final order. Commissioner Julie Brill did not participate.